The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes
Objective. To study the effect of liraglutide on the thickness of epicardial adipose tissue (EAT) in type 2 diabetes mellitus (T2DM) patients with abdominal obesity. Methods. Abdominal obesity T2DM patients with poor glycemic control were collected and treated with liraglutide. The changes of blood...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2021/5578216 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849387277801750528 |
|---|---|
| author | Na Zhao Xiaoying Wang Yongbo Wang Junjie Yao Chunhong Shi Jianling Du Ran Bai |
| author_facet | Na Zhao Xiaoying Wang Yongbo Wang Junjie Yao Chunhong Shi Jianling Du Ran Bai |
| author_sort | Na Zhao |
| collection | DOAJ |
| description | Objective. To study the effect of liraglutide on the thickness of epicardial adipose tissue (EAT) in type 2 diabetes mellitus (T2DM) patients with abdominal obesity. Methods. Abdominal obesity T2DM patients with poor glycemic control were collected and treated with liraglutide. The changes of blood glucose, blood lipid, waist circumference, body mass index (BMI), and EAT thickness were compared after 3 months of treatment with liraglutide. Cardiac magnetic resonance imaging (MRI) was used to measure EAT thickness. Results. After 3 months of treatment with liraglutide, glycosylated hemoglobin (HbA1c) decreased from 9.81±1.46% to 6.94±1.29% (95%CI=2.14–3.59, p<0.001). The weight decreased from 91.67±16.29 kg to 87.29±16.43 kg (95%CI=2.97–5.79, p<0.001). Waist circumference before treatment was 103.69±9.14 cm, and after treatment was 96.42±8.42 cm (95%CI=5.04–9.50, p<0.001). Total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) were significantly lower than those before treatment. TC decreased from 5.34±1.05 mmol/L to 4.86±0.97 mmol/L (95%CI=0.15–0.82, p<0.001). TG was 1.89 (1.48-3.17) and then to 1.92±0.69 (p=0.03). LDL-C decreased from 3.39±0.84 mmol/L to 3.01±0.74 mmol/L (95%CI=0.17–0.59, p=0.001). HDL-C increased by 1.7% after treatment, with no significant difference (p=0.062). More importantly, the thickness of EAT decreased from 5.0 (5.0-7.0) mm to 3.95±1.43 mm (p<0.001) after liraglutide administered for 3 months. Conclusion. Liraglutide significantly reduces EAT thickness in T2DM with abdominal obesity, which provides theoretical support for the cardiovascular benefits of liraglutide. |
| format | Article |
| id | doaj-art-2f54444904f94ecf8e2a1a3f259366e6 |
| institution | Kabale University |
| issn | 2314-6753 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-2f54444904f94ecf8e2a1a3f259366e62025-08-20T03:55:16ZengWileyJournal of Diabetes Research2314-67532021-01-01202110.1155/2021/5578216The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 DiabetesNa Zhao0Xiaoying Wang1Yongbo Wang2Junjie Yao3Chunhong Shi4Jianling Du5Ran Bai6Department of Endocrinology and MetabolismDepartment of Endocrinology and MetabolismDepartment of Endocrinology and MetabolismDepartment of Endocrinology and MetabolismDepartment of Endocrinology and MetabolismDepartment of Endocrinology and MetabolismDepartment of Endocrinology and MetabolismObjective. To study the effect of liraglutide on the thickness of epicardial adipose tissue (EAT) in type 2 diabetes mellitus (T2DM) patients with abdominal obesity. Methods. Abdominal obesity T2DM patients with poor glycemic control were collected and treated with liraglutide. The changes of blood glucose, blood lipid, waist circumference, body mass index (BMI), and EAT thickness were compared after 3 months of treatment with liraglutide. Cardiac magnetic resonance imaging (MRI) was used to measure EAT thickness. Results. After 3 months of treatment with liraglutide, glycosylated hemoglobin (HbA1c) decreased from 9.81±1.46% to 6.94±1.29% (95%CI=2.14–3.59, p<0.001). The weight decreased from 91.67±16.29 kg to 87.29±16.43 kg (95%CI=2.97–5.79, p<0.001). Waist circumference before treatment was 103.69±9.14 cm, and after treatment was 96.42±8.42 cm (95%CI=5.04–9.50, p<0.001). Total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) were significantly lower than those before treatment. TC decreased from 5.34±1.05 mmol/L to 4.86±0.97 mmol/L (95%CI=0.15–0.82, p<0.001). TG was 1.89 (1.48-3.17) and then to 1.92±0.69 (p=0.03). LDL-C decreased from 3.39±0.84 mmol/L to 3.01±0.74 mmol/L (95%CI=0.17–0.59, p=0.001). HDL-C increased by 1.7% after treatment, with no significant difference (p=0.062). More importantly, the thickness of EAT decreased from 5.0 (5.0-7.0) mm to 3.95±1.43 mm (p<0.001) after liraglutide administered for 3 months. Conclusion. Liraglutide significantly reduces EAT thickness in T2DM with abdominal obesity, which provides theoretical support for the cardiovascular benefits of liraglutide.http://dx.doi.org/10.1155/2021/5578216 |
| spellingShingle | Na Zhao Xiaoying Wang Yongbo Wang Junjie Yao Chunhong Shi Jianling Du Ran Bai The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes Journal of Diabetes Research |
| title | The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes |
| title_full | The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes |
| title_fullStr | The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes |
| title_full_unstemmed | The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes |
| title_short | The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes |
| title_sort | effect of liraglutide on epicardial adipose tissue in type 2 diabetes |
| url | http://dx.doi.org/10.1155/2021/5578216 |
| work_keys_str_mv | AT nazhao theeffectofliraglutideonepicardialadiposetissueintype2diabetes AT xiaoyingwang theeffectofliraglutideonepicardialadiposetissueintype2diabetes AT yongbowang theeffectofliraglutideonepicardialadiposetissueintype2diabetes AT junjieyao theeffectofliraglutideonepicardialadiposetissueintype2diabetes AT chunhongshi theeffectofliraglutideonepicardialadiposetissueintype2diabetes AT jianlingdu theeffectofliraglutideonepicardialadiposetissueintype2diabetes AT ranbai theeffectofliraglutideonepicardialadiposetissueintype2diabetes AT nazhao effectofliraglutideonepicardialadiposetissueintype2diabetes AT xiaoyingwang effectofliraglutideonepicardialadiposetissueintype2diabetes AT yongbowang effectofliraglutideonepicardialadiposetissueintype2diabetes AT junjieyao effectofliraglutideonepicardialadiposetissueintype2diabetes AT chunhongshi effectofliraglutideonepicardialadiposetissueintype2diabetes AT jianlingdu effectofliraglutideonepicardialadiposetissueintype2diabetes AT ranbai effectofliraglutideonepicardialadiposetissueintype2diabetes |